{"id":820954,"date":"2025-03-03T16:52:05","date_gmt":"2025-03-03T21:52:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/"},"modified":"2025-03-03T16:52:05","modified_gmt":"2025-03-03T21:52:05","slug":"investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/","title":{"rendered":"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MELBOURNE, Australia and INDIANAPOLIS, March  04, 2025  (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company\u2019s late-stage and next-generation radiotherapeutic candidates in urologic oncology.<\/p>\n<p align=\"justify\">In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers:<\/p>\n<ul>\n<li>Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute in Salt Lake City, UT, will discuss the ProstACT Global Phase 3 trial of TLX591 (<sup>177<\/sup>Lu rosopatamab tetraxetan), Telix\u2019s lead radio antibody-drug conjugate (rADC) therapy candidate in prostate cancer.<\/li>\n<li>Eric Jonasch, MD, Professor of Medicine in the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center in Houston, TX, will discuss the STARLITE studies of TLX250 (<sup>177<\/sup>Lu girentuximab) in combination with immunotherapy, in clear cell renal cell carcinoma.<\/li>\n<li>Rodney Hicks, MD, Professor of Medicine at the University of Melbourne and Monash University; Founder, Chair, and Chief Medical Officer at the Melbourne Theranostic Innovation Centre in Australia, will discuss TLX592 (<sup>64<\/sup>Cu\/<sup>225<\/sup>Ac RADmAb<sup>\u00ae<\/sup>) and the role of targeted alpha therapies in the treatment of prostate cancer.<\/li>\n<\/ul>\n<p>\n        <strong>The webinar will be held on: <\/strong>\n      <\/p>\n<p>\n        <strong>EDT: <\/strong>Tuesday March 11, 5.30pm <br \/><strong>AEDT<\/strong>: Wednesday March 12, 8.30am <br \/>The event will run for approximately 1.5 hours.<\/p>\n<p>Participants can register for the webcast at the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NLmkV14bTyh_u5grQxg6gmGI_xSJkI4mqHF_HzqVodWsowp2vtkgNTTT3tvnrk-f7Y4wxIPNAvwPg56VCXQuAYlqm5BizSagJ5wxIOYnltE073dgI5RaJXSu4g43Zyd9_-tcu0hMoFmXLoyu7T-Zy--Pbwd7cflfwHzqyAd1388=\" rel=\"nofollow\" target=\"_blank\">https:\/\/edge.media-server.com\/mmc\/p\/39s4k7gw\\<\/a><\/p>\n<p align=\"justify\">\n        <strong>About <\/strong><br \/>\n        <strong>Telix Pharmaceuticals Limited <\/strong>\n      <\/p>\n<p align=\"justify\">Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). TLX591, TLX592 and TLX250 have not received a marketing authorization in any jurisdiction.<\/p>\n<p align=\"justify\">Visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6zF-nE7bVNDxS9cjah1h7VCVidg_1EPJyXJE19fV2DstbVcroUJoSOV9x3ELfi0_kEvXIX8N4SzGs6W13BfnNgUy9RaL4GFnN1qQMuADHEM=\" rel=\"nofollow\" target=\"_blank\">www.telixpharma.com<\/a> for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TCLK-G6QfkpkecpH-oQnX6jOyXPOMEUiKpWI7n0__CUb-62usvj9H_edMdEwmUguT1BypTdAMEvjpeyqN5Ll7vBd716m4gLb6fimrvNUE6g=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=re06d7VmdfIuF7hNy9FqbY08JMQM0I-xyrU115XamZ1Ps20g-h5pGvQ_6ax1uDEb2gjo9Ys65VS6xj6dah5uKA==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gtX6lLfOa-OksX3gsQc4o5i-VnHs53eDok2_RFKtanHSQV13M5WheuQFTIf3K0gvmDtvAzRWA52hLbfYiqYaDgCxHjOoeka2OLoMtJo0hNQ=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Telix Investor Relations<\/strong>\n      <\/p>\n<p align=\"justify\">Ms. Kyahn Williamson<br \/>Telix Pharmaceuticals Limited<br \/>SVP Investor Relations and Corporate Communications<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hMCLUuYtlif8nYzy7Ga53fLxmc_HIr3tAEdCn0SqWddSFn_vkLQ-0EGlTGELpC_yDTVBC9sYXgWkTnUwlZtcK0qt2t7JiAXkYh51qdF7SObXG1M9cXmNneiygcHO3Rpi\" rel=\"nofollow\" target=\"_blank\">kyahn.williamson@telixpharma.com<\/a><\/p>\n<p>\n        <em>This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. <\/em>\n      <\/p>\n<p align=\"center\">Legal Notices<\/p>\n<p align=\"justify\">\n        <em>You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. <\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. \u00a0To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. <\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as \u201cmay\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cplan\u201d, \u201cestimate\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201coutlook\u201d, \u201cforecast\u201d and \u201cguidance\u201d, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix\u2019s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix\u2019s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix\u2019s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix\u2019s preclinical and clinical trials, and Telix\u2019s research and development programs; Telix\u2019s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix\u2019s product candidates, manufacturing activities and product marketing activities; Telix\u2019s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix\u2019s product candidates, if or when they have been approved; Telix\u2019s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix\u2019s expenses, future revenues and capital requirements; Telix\u2019s financial performance; developments relating to Telix\u2019s competitors and industry; and the pricing and reimbursement of Telix\u2019s product candidates, if and after they have been approved. Telix\u2019s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. <\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>\u00a92025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals\u00ae, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates \u2013 all rights reserved. Trademark registration status may vary from country to country.<\/em>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODIyMSM2Nzg3MTg1IzIwODMyNDI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGU0NjYxYzItMGUwMi00MTk1LTk4YjItYTkzN2UxMTYzOGZjLTEwOTQ4MTM=\/tiny\/Telix-Pharmaceuticals-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MELBOURNE, Australia and INDIANAPOLIS, March 04, 2025 (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company\u2019s late-stage and next-generation radiotherapeutic candidates in urologic oncology. In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers: Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute in Salt Lake City, UT, will discuss the ProstACT Global Phase 3 trial of TLX591 (177Lu rosopatamab tetraxetan), Telix\u2019s lead radio antibody-drug conjugate (rADC) therapy candidate in prostate cancer. Eric Jonasch, MD, Professor of Medicine in the Department of Genitourinary &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-820954","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MELBOURNE, Australia and INDIANAPOLIS, March 04, 2025 (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company\u2019s late-stage and next-generation radiotherapeutic candidates in urologic oncology. In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers: Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute in Salt Lake City, UT, will discuss the ProstACT Global Phase 3 trial of TLX591 (177Lu rosopatamab tetraxetan), Telix\u2019s lead radio antibody-drug conjugate (rADC) therapy candidate in prostate cancer. Eric Jonasch, MD, Professor of Medicine in the Department of Genitourinary &hellip; Continue reading &quot;Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-03T21:52:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODIyMSM2Nzg3MTg1IzIwODMyNDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum\",\"datePublished\":\"2025-03-03T21:52:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\\\/\"},\"wordCount\":1006,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODIyMSM2Nzg3MTg1IzIwODMyNDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\\\/\",\"name\":\"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODIyMSM2Nzg3MTg1IzIwODMyNDI=\",\"datePublished\":\"2025-03-03T21:52:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODIyMSM2Nzg3MTg1IzIwODMyNDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODIyMSM2Nzg3MTg1IzIwODMyNDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/","og_locale":"en_US","og_type":"article","og_title":"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum - Market Newsdesk","og_description":"MELBOURNE, Australia and INDIANAPOLIS, March 04, 2025 (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company\u2019s late-stage and next-generation radiotherapeutic candidates in urologic oncology. In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers: Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute in Salt Lake City, UT, will discuss the ProstACT Global Phase 3 trial of TLX591 (177Lu rosopatamab tetraxetan), Telix\u2019s lead radio antibody-drug conjugate (rADC) therapy candidate in prostate cancer. Eric Jonasch, MD, Professor of Medicine in the Department of Genitourinary &hellip; Continue reading \"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-03T21:52:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODIyMSM2Nzg3MTg1IzIwODMyNDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum","datePublished":"2025-03-03T21:52:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/"},"wordCount":1006,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODIyMSM2Nzg3MTg1IzIwODMyNDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/","name":"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODIyMSM2Nzg3MTg1IzIwODMyNDI=","datePublished":"2025-03-03T21:52:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODIyMSM2Nzg3MTg1IzIwODMyNDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODIyMSM2Nzg3MTg1IzIwODMyNDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=820954"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820954\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=820954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=820954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=820954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}